Loading…

Statutory Instruments

2026 No. 614

NATIONAL HEALTH SERVICE, ENGLAND AND WALES

NATIONAL HEALTH SERVICE, SCOTLAND

HEALTH AND PERSONAL SOCIAL SERVICES, NORTHERN IRELAND

The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026

Made

9th June 2026

Laid before Parliament

10th June 2026

Coming into force

1st July 2026

The Secretary of State for Health and Social Care makes the following Regulations in exercise of the powers conferred by sections 263(1)(b) and (c), (2) and (5), 264(3), 266(1) and 272(7)(a) and (b) and (8) of the National Health Service Act 2006(1) having had regard to the matters specified in section 266(3), (4) and (4A) of that Act.

The Secretary of State has consulted in accordance with sections 263(1) and (1A) of that Act.

Citation, commencement and extent

1.—(1) These Regulations may be cited as the Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 and come into force on 1st July 2026.

(2) These Regulations extend to England and Wales, Scotland and Northern Ireland.

Amendments to the Branded Health Service Medicines (Costs) Regulations 2018

2.—(1) Regulation 3 (payment scheme) of the Branded Health Service Medicines (Costs) Regulations 2018(2) is amended as follows.

(2) In paragraph (1), for the table substitute the following table—

Table

Applicable Period Newer presentation payment percentage Older presentation payment percentage
1st July 2026 to the end of 2026 16.5% 11%
1st January 2027 to the end of 2027 and any subsequent calendar year 16.5% 10.9%.

(3) In paragraph (1AB)—

(a)for “1st July 2025 and ending at the end of 2025”, substitute “1st July 2026 and ending at the end of 2026”; and

(b)for “31.3% and not 23.4%”, substitute “8.7% and not 16.5%”.

(4) In paragraph (1AC)—

(a)for “1st July 2025 and ending at the end of 2025”, substitute “1st July 2026 and ending at the end of 2026”;

(b)in sub-paragraph (a), for “1st January 2025 and ending at the end of 30 June 2025”, substitute “1st January 2026 and ending at the end of 30 June 2026”; and

(c)in sub-paragraph (b), for “15.5%”, substitute “24.3%”.

Signed by the authority of the Secretary of State for Health and Social Care

Preet Kaur Gill

Parliamentary Under-Secretary of State

9th June 2026

Department of Health and Social Care

(1)

2006 c. 41. Section 263 was amended by the Health Service Medical Supplies (Costs) Act 2017 (c. 23) (“the 2017 Act”), sections 5 and 10(5). Section 264 was amended by the 2017 Act, section 10(6). Section 266 was amended by the 2017 Act, sections 6(5) to (9) and 7(6). See section 275(1) of the National Health Service Act 2006 for definition of “regulations” that is relevant to the powers being exercised.

(2)

S.I. 2018/345. Relevant amending instruments are S.I. 2018/1255, 2020/258, 2022/593, 2023/239, 2023/1307, 2024/1277 and 2025/667.

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
The Branded Health Service Medicines (Costs) (Amendment) Regulations 2026 (2026/614)
Version from: original only

Displaying information

Status of this instrument

in force Provision is in force
in force* In force only for specified purposes (for detail about the purposes see/hover footnote)
not in force Not in force in England (may be in force in other geographies, see footnotes)
italics Defined term
dfn Defined term (alternative style)
gry bckgrd the in-force status of the provision is complex, check the footnotes

Status of changes to instrument text

The list includes made instruments, both those in force and those yet to come into force. Typically, instruments that are not yet in force (hence their changes are not incorporated into the text above) are indicated by description 'not yet' in the changes made column.